Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

REGENXBIO Inc. - Common Stock (NQ:RGNX)

9.490 -0.110 (-1.15%)
Streaming Delayed Price Updated: 10:30 AM EDT, Jul 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about REGENXBIO Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
The market is filled with gapping stocks in Friday's session. ↗
Via Chartmill
What's going on in today's pre-market session ↗
Via Chartmill
Thursday's after hours session: top gainers and losers ↗
Via Chartmill
News headline image
Regenxbio (RGNX) Q1 2026 Earnings Transcript ↗
Regenxbio (RGNX) Q1 2026 Earnings Transcript 
Via The Motley Fool
REGENXBIO INC (NASDAQ:RGNX) Plunges 17% on Q1 Revenue Miss Despite Positive DMD Gene Therapy Trial Results ↗
Via Chartmill
REGENXBIO INC (NASDAQ:RGNX) Stock Plunges 15% After Q4 Earnings Miss ↗
Via Chartmill
RGNX Shares Pare Losses As Wall Street Dismisses Gene Therapy Clinical Hold Spurred Selloff As An Overreaction ↗
Via Stocktwits
These stocks are moving in today's session ↗
Via Chartmill
What's going on in today's session ↗
Via Chartmill
Which stocks are gapping on Thursday? ↗
Via Chartmill
Discover the top movers in Thursday's pre-market session. ↗
Via Chartmill
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH
On March 25, 2026, the landscape of neurodegenerative medicine underwent a seismic shift. The U.S. Food and Drug Administration (FDA) granted accelerated approval to Denali Therapeutics (NASDAQ: DNLI)... 
Via Finterra
Topics Economy Initial Public Offering
News headline image
Regenxbio Says Its Gene Therapy For Muscle Disorder Showed No Evidence Of Liver Injury In Study ↗
The investigational gene therapy RGX-202 exhibited a favorable safety profile with no serious adverse events and no evidence of liver injury, the company said. 
Via Stocktwits
Topics Death
News headline image
REGENXBIO (RGNX) Q4 2025 Earnings Call Transcript ↗
REGENXBIO (RGNX) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
QURE Or RGNX: Which Gene Therapy Was FDA Chief Really Warning About In Rare Disease Remarks? ↗
Analysts are divided on the target, with RBC Capital and Stifel saying the comments appeared to reference uniQure, while Leerink argued they more closely align with Regenxbio’s RGX-121. 
Via Stocktwits
News headline image
FDA Commissioner Refers To Rare Disease Drug With Associated Morbidity: Analysts Are Divided If Makary Meant Regenxbio Or Uniqure’s Experimental Therapy ↗
Following the comments, shares of both Regenxbio and uniQure traded in the red. 
Via Stocktwits
News headline image
Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy ↗
While Sarepta’s gene therapy for the treatment of DMD called Elevidys was approved by the FDA in 2023, Regenxbio is developing its treatment. 
Via Stocktwits
Topics Intellectual Property Lawsuit
News headline image
Retina’s ‘Sustained’ Moment: Ocular Therapeutix Braces for Game-Changing Phase 3 AXPAXLI Data
The multi-billion dollar wet Age-Related Macular Degeneration (wet AMD) market is standing on the precipice of a transformative shift. Today, February 16, 2026, Ocular Therapeutix (NASDAQ: OCUL) is in... 
Via MarketMinute
News headline image
Biotech Beat Nvidia in 2025. Can It Do It Again? ↗
Big pharma and biotech take the earnings stage with reports from Eli Lilly and Novo Nordisk leading the lineup. Will they help the industry once again outperform AI champ Nvidia? 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Regenxbio Stock Still Has Over 300% Upside Despite FDA Pushback On Hunter Syndrome Drug: Clear Street ↗
Clear Street pointed to strength in RGX-202 data for Duchenne and early results from Sura-Vec in wet AMD. 
Via Stocktwits
News headline image
Why Did RGNX Shares Plummet 19% After-Hours Today? ↗
REGENXBIO said on Monday that the U.S. Food and Drug Administration (FDA) denied approval for its gene therapy in treating Hunter syndrome, outlining several reasons for the denial. 
Via Stocktwits
Monday's after hours session: top gainers and losers ↗
Via Chartmill
Gapping stocks in Wednesday's session ↗
Via Chartmill
News headline image
RGNX Stock Is Falling Today — What Is The FDA Update On REGENXBIO's Gene Therapy? ↗
REGENXBIO stated that the FDA has placed a clinical hold on the company’s experimental gene therapy program for the treatment of rare childhood diseases. 
Via Stocktwits
Top movers in Wednesday's pre-market session ↗
Via Chartmill
News headline image
My Top 4 Stocks to Buy in Early 2026 ↗
These stocks offer impressive long-term upside with downside protection. 
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results
December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an... 
Via MarketMinute
News headline image
REGENXBIO (RGNX) Q3 2025 Earnings Call Transcript ↗
REGENXBIO (RGNX) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
REGENXBIO INC (NASDAQ:RGNX) Tops Q3 2025 Estimates, Shares Rise on Strong Results and Pipeline Progress ↗
REGENXBIO beats Q3 2025 earnings estimates with strong revenue and a narrower loss. Key gene therapy RGX-202 advances, with topline data expected in early 2026. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.